Evaxion AS ADR EVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
-
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
-
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
-
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
-
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
-
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
-
Evaxion announces business update and second quarter 2026 financial results
-
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
Trading Information
- Previous Close Price
- $2.96
- Day Range
- $2.97–3.16
- 52-Week Range
- $2.72–6.92
- Bid/Ask
- $2.93 / $3.07
- Shares Outstanding
- 9.22M
- Market Cap
- $26.79M
- Volume/Avg
- 27,622 / 228,571
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.90
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 46
- Website
- https://www.evaxion.ai
Valuation
|
Metric
|
EVAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.60 |
Price/Sales | 2.90 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVAX
|
|---|---|
Quick Ratio | 5.06 |
Current Ratio | 5.06 |
Interest Coverage | −3.26 |
Quick Ratio
EVAX
Profitability
|
Metric
|
EVAX
|
|---|---|
Return on Assets (Normalized) | −33.52% |
Return on Equity (Normalized) | −180.00% |
Return on Invested Capital (Normalized) | −35.33% |
Return on Assets
EVAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|B^V>f^ | LOCK|<nLW | $139B | |||
| Moderna Inc
MRNA
| LOCK|jxtPd? | LOCK|?G< | $103B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|PR<^!! | LOCK|nTxBd | $96B | |||
| argenx SE ADR
ARGX
| LOCK|LkHpXF | LOCK|gw | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r^VD?@# | LOCK|jk | $45B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|fRN#m&N | LOCK|<f<%? | $30B | |||
| Incyte Corp
INCY
| LOCK|l$<jwB | LOCK|JG | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@L?xZ<h | LOCK|S!D | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Gt^&Bq | LOCK|cbz& | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|VT<lx<l | LOCK|C#X | $15B |
United States